dalteparin has been researched along with Sepsis in 14 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A diagnosis of cavernous sinus thrombosis was made based on clinical findings and confirmed by imaging in both patients." | 1.33 | Septic thrombosis of the cavernous sinus: two different mechanisms. ( Looi, A; Pavlovich, P; Rootman, J, 2006) |
| "Thromboprophylaxis with 60 mg enoxaparin daily, in split doses, starting before surgery, is safe and appropriate in patients with hip fractures." | 1.31 | Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. ( Greiner, N; Korninger, C; Roller, RE; Sim, E; Thaler, HW, 2001) |
| "Venous thrombosis is a very rare occurrence in patients with haemophilia A." | 1.31 | Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A. ( Allan, PL; Dennis, R; Ludlam, CA; Manson, LM; Stewart, AJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Oudemans-van Straaten, HM | 1 |
| van Schilfgaarde, M | 1 |
| Molenaar, PJ | 1 |
| Wester, JP | 1 |
| Leyte, A | 1 |
| Meher, MK | 1 |
| Poluri, KM | 1 |
| Kaenkumchorn, T | 1 |
| Kesavan, A | 1 |
| Darwish, OS | 1 |
| Strube, S | 1 |
| Nguyen, HM | 1 |
| Tanios, MA | 1 |
| Al Otair, HA | 1 |
| Abdel Gader, AG | 1 |
| Khurshid, SM | 1 |
| Alzeer, AH | 1 |
| Al Momen, AK | 1 |
| Al Shaikh, M | 1 |
| Al Gahtani, F | 1 |
| Al Aseri, ZA | 1 |
| Abdelrazik, HA | 1 |
| Hanify, JM | 1 |
| Dupree, LH | 1 |
| Johnson, DW | 1 |
| Ferreira, JA | 1 |
| Zenáhlíková, Z | 1 |
| Kvasnicka, J | 1 |
| Kudrnová, Z | 1 |
| Sudrová, M | 1 |
| Brzezková, R | 1 |
| Mazoch, J | 1 |
| Malíková, I | 1 |
| Vyborny, J | 1 |
| Erhart, D | 1 |
| Pecen, L | 1 |
| Lauretta, A | 1 |
| Almoudaris, AM | 1 |
| Jiao, LR | 1 |
| Olah, Z | 1 |
| Kerenyi, A | 1 |
| Kappelmayer, J | 1 |
| Schlammadinger, A | 1 |
| Razso, K | 1 |
| Boda, Z | 1 |
| Thaler, HW | 1 |
| Roller, RE | 1 |
| Greiner, N | 1 |
| Sim, E | 1 |
| Korninger, C | 1 |
| Usenko, LV | 1 |
| Garmish, OS | 1 |
| Zabashnyĭ, SI | 1 |
| Stadnichuk, GN | 1 |
| Ovchinnikova, LIu | 1 |
| Biriukov, VV | 1 |
| Østergaard, S | 1 |
| Hvas, AM | 1 |
| Medrud, L | 1 |
| Fuglsang, J | 1 |
| Pavlovich, P | 1 |
| Looi, A | 1 |
| Rootman, J | 1 |
| Stewart, AJ | 1 |
| Manson, LM | 1 |
| Dennis, R | 1 |
| Allan, PL | 1 |
| Ludlam, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328] | Phase 4 | 14 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)[NCT04406389] | Phase 4 | 14 participants (Actual) | Interventional | 2020-10-13 | Terminated (stopped due to Low accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm (NCT04406389)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intermediate Dose Prophylaxis | 0 |
| Therapeutic Dose Anticoagulation | 2 |
Comparison of length of ICU stay in days between each treatment arm. (NCT04406389)
Timeframe: 6 months
| Intervention | Days (Median) |
|---|---|
| Intermediate Dose Prophylaxis | 25.5 |
| Therapeutic Dose Anticoagulation | 25 |
Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment arm (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | ||
|---|---|---|---|
| Venous Thromboembolism Events | Arterial Thrombosis Events | Microthrombosis Events | |
| Intermediate Dose Prophylaxis | 1 | 1 | 0 |
| Therapeutic Dose Anticoagulation | 0 | 0 | 1 |
Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria. (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | |
|---|---|---|
| Major Bleeding Events | Clinically Relevant Non-Major Bleeding Events | |
| Intermediate Dose Prophylaxis | 1 | 1 |
| Therapeutic Dose Anticoagulation | 1 | 2 |
1 trial available for dalteparin and Sepsis
| Article | Year |
|---|---|
Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; APACHE; Blood Coagulation; Critical Illness; Cross | 2009 |
13 other studies available for dalteparin and Sepsis
| Article | Year |
|---|---|
Bifunctional Dalteparin/Enoxaparin coated nanosilver formulation to prevent bloodstream infections during hemodialysis.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Renal Dialys | 2022 |
A Rare Complication of Campylobacter Sepsis in an Infant.
Topics: Anti-Bacterial Agents; Anticoagulants; Campylobacter Infections; Campylobacter jejuni; Ceftriaxone; | 2018 |
Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heparin; Humans; I | 2013 |
The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.
Topics: Adult; Aged; Anticoagulants; APACHE; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Case-Co | 2016 |
Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Heparin; Hospitalization; Humans; Incide | 2017 |
FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Enoxaparin; Factor Xa Inhibitors; | 2010 |
Septic thrombophlebitis of portal vein: unusual presentation of appendicitis.
Topics: Adult; Anticoagulants; Appendectomy; Appendicitis; Diagnosis, Differential; Enoxaparin; Follow-Up St | 2011 |
Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antigen-Antibody Complex; Enoxaparin; Extremities; Fem | 2012 |
Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; Drug Administration Schedule; Enoxapari | 2001 |
[Application of clexane in urosepsis: necessity or the issue of fashion].
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Sepsis; Urologic Diseases | 2001 |
Ovarian vein thrombosis after delivery.
Topics: Adult; Cesarean Section; Delivery, Obstetric; Diagnosis, Differential; Female; Follow-Up Studies; He | 2018 |
Septic thrombosis of the cavernous sinus: two different mechanisms.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Cavernous Sinus Thrombosis; Drug Therapy, Combination; | 2006 |
Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A.
Topics: Adult; Factor VIII; Femoral Vein; Fibrinolytic Agents; Hemophilia A; Heparin, Low-Molecular-Weight; | 2000 |